Literature DB >> 432816

Neutrophil function in surgical patients: in vitro correlation of abnormal neutrophil chemotaxis by Levamisole.

N V Christou, J L Meakins.   

Abstract

Cutaneous anergy to recall skin test antigens is associated with decreased polymorphonuclear neutrophil (PMN) chemotaxis (CTX). This decreased PMN chemotaxis is mediated by factors circulating in the sera (AS) from patients with anergy. Levamisole hydrochloride will correct the chemotactic defect of neutrophils from anergic patients, in vitro, from 96.2 +/- 1.2 to 125.1 +/- 1.7 microns at concentrations of 10(-3) M to 10(-18) M. Pretreatment of normal PMN with Levamisole at 10(-4) M will protect them from the chemotactic inhibiting effect of AS. Normal PMN migrating in the normal range, 128.1+/- 2.7 microns, can be made to behave like anergic PMN by treatment with AS. These PMN which now migrate in the anergic range 92.1 +/- 1.7 microns can be converted back to normal by Levamisole treatment at 10(-3) M to 10(-18) M. In 35 surgical patients who demonstrated the spectrum of decreased PMN CTX, the majority toward the anergy level, Levamisole improved the PMN CTX toward normal levels in every instance, while not affecting the CTX of the normally migrating PMN.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 432816

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  3 in total

1.  Analysis of the linear under-agarose leukocyte chemotaxis assay.

Authors:  C Rothman; D Lauffenburger
Journal:  Ann Biomed Eng       Date:  1983       Impact factor: 3.934

2.  Reduction of operative morbidity and mortality by combined preoperative and postoperative nutritional support.

Authors:  J L Mullen; G P Buzby; D C Matthews; B F Smale; E F Rosato
Journal:  Ann Surg       Date:  1980-11       Impact factor: 12.969

3.  Therapeutic approaches to anergy in surgical patients. Surgery and levamisole.

Authors:  J L Meakins; N V Christou; H M Shizgal; L D MacLean
Journal:  Ann Surg       Date:  1979-09       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.